Research Article
Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study
Table 3
Safety profile of the 68 elderly patients with advanced NSCLC who received PD-1 inhibitor monotherapy.
| | Adverse reactions | Total (N, %) | Grade 1–2 (N, %) | Grade ≥3 (N, %) |
| | Adverse reactions | 48 (70.6) | | 11 (16.2) | | Fatigue | 17 (25.0) | 14 (20.6) | 3 (4.4) | | Diarrhea | 15 (22.1) | 13 (19.2) | 2 (2.9) | | Rash | 11 (16.2) | 10 (14.7) | 1 (1.5) | | Abnormal liver function | 10 (14.7) | 4 (5.9) | 6 (8.8) | | Nausea and vomiting | 7 (10.3) | 5 (7.4) | 2 (2.9) | | Pneumonitis | 5 (7.4) | 4 (5.9) | 1 (1.5) | | RCCEP | 5 (7.4) | 5 (7.4) | 0 (0.0) | | Fever | 3 (4.4) | 3 (4.4) | 0 (0.0) | | Stomatitis | 2 (2.9) | 2 (2.9) | 0 (0.0) |
|
|
NSCLC, non-small cell lung cancer; RCCEP: Reactive cutaneous capillary endothelial proliferation; PD-1, programmed cell death protein 1.
|
